Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Convalescent Plasma  COVID-19 treatment studies for Conv. Plasma  C19 studies: Conv. Plasma  Conv. Plasma   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality -323% Improvement Relative Risk Mortality (b) -114% Ventilation -221% Hospitalization time 25% Improvement in Ct value 32% Bajpai et al. Conv. Plasma for COVID-19 RCT LATE Is late treatment with convalescent plasma beneficial for COVID-19? RCT 29 patients in India Higher mortality (p=0.22) and ventilation (p=0.33), not stat. sig. Bajpai et al., medRxiv, doi:10.1101/2020.10.25.20219337 Favors conv. plasma Favors control

Efficacy of Convalescent Plasma Therapy compared to Fresh Frozen Plasma in Severely ill COVID-19 Patients: A Pilot Randomized Controlled Trial

Bajpai et al., medRxiv, doi:10.1101/2020.10.25.20219337 (Preprint)
Bajpai et al., Efficacy of Convalescent Plasma Therapy compared to Fresh Frozen Plasma in Severely ill COVID-19 Patients: A.., medRxiv, doi:10.1101/2020.10.25.20219337 (Preprint)
Oct 2020   Source   PDF  
  All Studies   Meta
Small RCT 29 patients in India, 14 treated with convalescent plasma, not showing significant differences with treatment.
risk of death, 323.0% higher, HR 4.23, p = 0.22, treatment 3 of 14 (21.4%), control 1 of 15 (6.7%), adjusted per study, 28 days, Cox proportional hazards.
risk of death, 114.3% higher, RR 2.14, p = 0.60, treatment 2 of 14 (14.3%), control 1 of 15 (6.7%), 7 days.
risk of mechanical ventilation, 221.4% higher, RR 3.21, p = 0.33, treatment 3 of 14 (21.4%), control 1 of 15 (6.7%), 7 days.
hospitalization time, 24.8% lower, relative time 0.75, p = 0.08, treatment 14, control 15.
relative improvement in Ct value, 32.5% better, RR 0.68, p = 0.11, treatment 14, control 15.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Bajpai et al., 27 Oct 2020, Randomized Controlled Trial, India, preprint, 20 authors.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperConv. PlasmaAll
Efficacy of Convalescent Plasma Therapy compared to Fresh Frozen Plasma in Severely ill COVID-19 Patients: A Pilot Randomized Controlled Trial
Dr Meenu Bajpai, Dr Suresh Kumar, Dr Ashish Maheshwari, Dr Karan Chhabra, Pratibha Kale, Dr Amita Gupta, Dr Ashad Narayanan, Dr Ekta Gupta, Dr Nirupama Trehanpati, Dr Chhagan Bihari, Dr Reshu Agarwal, Kamini Gupta, Upendra Kumar Gupta, Dr Ankit Bhardwaj, Dr Guresh Kumar, M.Sc Mojahidul Islam, Ravinder Singh, M.Sc Pushpa Yadav, Dr Rakhi Maiwall, Dr Shiv Kumar Sarin
All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
Conflict of Interest: None declared. Acknowledgements: We thank Mr Pankaj Jain for his technical support in the trial.
Cao, Wang, Wen, Liu, Wang et al., A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19, N Engl J Med
Chen, Xiong, Bao, Shi, Convalescent plasma as a potential therapy for COVID-19, Lancet Infect Dis
Chen, Zhou, Dong, Qu, Gong et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, Lancet
De Brito, Lucena-Silva, Torres, Luna, Correia et al., The
Duan, Liu, Li, Zhang, Yu et al., Effectiveness of convalescent plasma therapy in severe COVID-19 patients, Proc Natl Acad Sci U S A
Grein, Ohmagari, Shin, Diaz, Asperges et al., Compassionate Use of Remdesivir for Patients with Severe Covid-19, N Engl J Med
Horby, Lim, Emberson, Mafham, Bell et al., Dexamethasone in Hospitalized Patients with Covid-19 -Preliminary Report, N Engl J Med
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Joyner, Wright, Fairweather, Senefeld, Bruno et al., Early safety indicators of COVID-19 convalescent plasma in 5000 patients, J Clin Invest
Li, Zhang, Hu, Tong, Zheng et al., Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial, JAMA
Ng, Oong, Lim, Chook, Takebe et al., Viral Load and Sequence Analysis Reveal the Symptom Severity, Diversity, and Transmission Clusters of Rhinovirus Infections, Clin Infect Dis
Shen, Wang, Zhao, Yang, Li et al., Treatment of 5 Critically Ill Patients with COVID-19 with Convalescent Plasma, JAMA
Wu, Mcgoogan, Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention, JAMA
Zhang, Liu, Tan, Huang, Dong et al., Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection, Chest
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop